QUECTEL-WIRELESS
26.6.2024 13:01:27 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, announced the launch of the FLM263D standalone Wi-Fi module that supports Alexa Connect Kit (ACK) SDK for Matter, enabling IoT devices to connect seamlessly with Matter compliant controllers including Amazon Alexa, Google Home, Samsung SmartThings, and Apple HomeKit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240626747648/en/
Quectel unveils FLM263D Wi-Fi module: Pioneering seamless connectivity with ACK SDK for Matter (Photo: Business Wire)
Matter stands as a pivotal standard in smart home communication, tackling the persistent challenges of compatibility and fragmentation within the sector by enabling direct communication between smart devices. Governed by the Connectivity Standards Alliance (CSA), Matter devices undergo a stringent certification process to ensure secure, reliable, and universally interoperable connections. Adherence to this certification is paramount for all Matter-compliant products, fostering a unified communication framework and enhancing user experiences.
“We created ACK to make it simpler for device makers to build smart home devices with a fully-managed service without having deep expertise in multiple wireless protocols, complex cloud connectivity, and the necessary maintenance of cloud infrastructure. We are excited about this launch because Quectel’s FLM263D adds to ACK's portfolio of available solutions and offers more choices for device makers,” says Ben McInnis, Director, Smart Home, Amazon.
“Revolutionizing connectivity in the smart home landscape, our latest FLM263D module sets a new standard for seamless integration,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “It also empowers developers with robust support for the ACK SDK for Matter, ensuring unparalleled interoperability and innovation in the IoT ecosystem.”
The FLM263D module is a 2.4GHz single band Wi-Fi 6 module, featuring a high-performance processor with a frequency of up to 320MHz. This innovative module boasts support for IEEE 802.11b/g/n/ax protocol and BLE 5.2, paired with built-in 512KB SRAM and 4MB flash for optimal performance. Furthermore, it meets rigorous security standards, including secure boot and mbed TLS encryption, ensuring robust protection for connected devices.
The FLM263D offers support for device certifications such as Works with Alexa (WWA) and features such as Matter Simple Setup (MSS). MSS allows end-users to seamlessly connect Matter-compliant smart home devices to Alexa with zero-touch setup, while WWA instils consumer confidence when buying on Amazon.
FLM263D offers five GPIO interfaces that can alternatively function as PWM or I2C communication channels. Designed with an LCC form factor, built-in PCB antenna, measuring a mere 17.3mm × 15.0mm × 2.8mm, and with an operating temperature range of -40°C to +105°C, 3.0~3.6V power supply, the FLM263D is perfectly suited for smart lighting applications, especially smart bulbs.
Additional modules will be rolled out very soon to expand the scope of Quectel offerings to include smart switches, smart plugs, and other smart household applications.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626747648/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom